| MFCV | muscle fiber conduction velocity |
|---|---|
| MNCV | motor nerve conduction velocity |
| NCS | National Collaborative Study; neocarcinostatin; nerve conduction study; newborn calf serum; no conce... |
| NCV | nerve conduction velocity; noncholera vibrio |
| NCVS | nerve conduction velocity study |
| bone marrow cells | The fat cells (adipocytes), large nucleated cells or myelocytes, and giant cells called megakaryocytes, filling the meshes making up the bone marrow, a meshwork of connective tissue containing branching fibres. (12 Dec 1998) |
|---|---|
| bone marrow dose | The cumulative dose to the blood-forming organ from therapeutic or nuclear fallout irradiation; the presumed leukemogenic dose. (05 Mar 2000) |
| bone marrow embolism | Obstruction of a vessel by bone marrow, usually following fracture of a bone. (05 Mar 2000) |
| bone marrow examination | Removal of bone marrow and evaluation of its histologic picture. (12 Dec 1998) |
| bone marrow harvesting | <procedure> A medical procedure which involves collecting healthy bone marrow which willbe stored and used in a future bone marrow transplant. (09 Oct 1997) |
| bone marrow neoplasms | Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as myeloma. most bone marrow neoplasms are metastatic. (12 Dec 1998) |
| bone marrow purging | Techniques for the removal of subpopulations of cells (usually residual tumour cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic bone marrow transplantation. (12 Dec 1998) |
| bone marrow suppression | <oncology, pharmacology> A side effect of many anticancer and antiviral drugs, including AZT. Bone marrow suppression leads to a decrease in white blood cells, red blood cells and platelets. Such reductions in turn result in anaemia, bacterial infections and spontaneous or excess bleeding. (09 Oct 1997) |
| bone marrow transplant | <procedure> A procedure in which a section of bone marrow is taken from one person and transplanted into another. It is used to replace bone marrow that has been damaged or diseased. It can be a treatment option in leukaemia. Acronym: BMT (16 Dec 1997) |
| bone marrow transplantation | <oncology, procedure> Treatment in which healthy bone marrow replaces bone marrow that has been affected by a disease or by treatment for a disease. Acronym: BMT (12 May 1997) |
| bone matrix | The intercellular substance of bone tissue consisting of collagen fibres, ground substance, and inorganic bone salts. (05 Mar 2000) |
| bone metastases | <radiology> Sensitivity . . . . . . . . . . . . . . . . . . . . . . . . . 98%, False negatives: multiple myeloma, thyroid carcinoma, small, purely lytic lesions, oat cell carcinoma Specificity . . . . . . . . . . . . . . . . . . . . . . . . High, False positives: Paget's disease, arthritis, fibrous dysplasia, infection, trauma, new or old REF: MacNeil BJ. Value of bone scanning in neoplastic disease. Semin Nucl Med 14:277, 1984. (12 Dec 1998) |
| bone metastases in kids | <radiology> Rhabdomyosarcoma, neuroblastoma, histiocytosis X Note: Wilms tumour goes to lung, not bone (12 Dec 1998) |
| bone morphogenetic protein | <protein> Activity derived from bone that induces the formation of cartilage and bone in vivo. Seven bone morphogenetic proteins have been described, BMP 1 being the only one not in the TGF beta superfamily. BMP 3 was formerly called osteogenin. Acronym: BMP (18 Nov 1997) |
| bone morphogenetic proteins | Non-collagenous factors, believed to be proteins, that occur in demineralised bone and stimulate osteogenesis. They can induce new bone formation in ectopic sites and thus have potential use in bone repair. (12 Dec 1998) |